What Happens Before You Receive a Mounjaro Prescription
Before a doctor prescribes Mounjaro in Singapore, the process should involve more than a brief request for medication. Mounjaro is a prescription-only medicine, and Singapore regulators have stressed that prescribing through telemedicine or clinic care must still meet proper standards of clinical assessment, documentation, and patient safety.
Key Takeaways
Mounjaro is not meant to be issued without an appropriate doctor assessment in Singapore.
Before prescribing, doctors usually review weight-related health risks, medical history, current medicines, and whether the treatment goal is clinically appropriate.
Telehealth may be part of the care pathway, but first-time prescribing still requires proper assessment, and some patients may need escalation to an in-person visit.
The pre-prescription stage is also when doctors discuss side effects, monitoring, and whether follow-up can be done safely.
Mounjaro should be understood as doctor-supervised treatment rather than a self-directed purchase.
Why there is a pre-prescription assessment
The purpose of the first assessment is to decide whether tirzepatide is clinically appropriate for that specific patient, not simply whether the medicine is available. In Singapore, HSA has registered Mounjaro as a prescription medicine, and MOH has separately cautioned against telemedicine practices where prescriptions are issued without proper clinical assessment, including concerns about first-time patients and inadequate consultations.
This matters because tirzepatide affects appetite regulation, glucose pathways, and gastrointestinal function. HSA’s benefit-risk assessment noted expected adverse effects such as nausea, diarrhoea, decreased appetite, vomiting, dyspepsia, and constipation, which is why prescribing is tied to clinical review rather than simple retail access.
What doctors usually review before prescribing
Weight history and current health risk
A doctor will usually start by understanding the patient’s weight trajectory rather than looking at a single number in isolation. That often includes present weight, previous weight changes, central adiposity, previous weight-management attempts, and whether excess weight is already affecting metabolic or cardiovascular risk. Singapore public-health resources and local obesity guidance use lower Asian BMI action thresholds than standard Western cut-offs, with BMI 23 kg/m² and above indicating increased risk and BMI 27.5 kg/m² and above indicating high risk for weight-related health problems in Asian populations.
This review helps the doctor place treatment in context. Local guidance also frames obesity management around medical risk, comorbidities, and realistic treatment goals rather than appearance-based targets alone.
Medical history and comorbidities
Before prescribing, doctors generally assess whether the patient has conditions that change the benefit-risk balance or affect monitoring needs. In practice, this often includes type 2 diabetes status, prediabetes, blood pressure issues, lipid disorders, sleep-related symptoms, gastrointestinal history, previous pancreatitis history, and broader cardiometabolic risk. HSA’s product information for Mounjaro notes limitations of use and warnings that make this clinical history important.
Even when the consultation is for weight management, the pre-prescription step is still a full medical assessment. That is because excess weight is commonly linked with diabetes, hypertension, cardiovascular disease, and other complications that may influence whether treatment is appropriate and how it should be followed up.
Current medicines and treatment conflicts
Doctors also review current medicines because new treatment should be considered alongside the patient’s existing regimen. This is especially relevant when a medicine affects glucose control, appetite, gastrointestinal tolerance, or dehydration risk. The aim is not only to decide whether tirzepatide can be started, but also whether dose changes, counselling, or closer monitoring may be needed. That expectation is consistent with Singapore’s professional requirement that doctors provide competent care and act in the patient’s best interests.
Whether the patient is suitable for telehealth or needs in-person review
Not every patient is equally suitable for remote initiation. MOH has stated that prescribing without proper clinical assessment is unacceptable, and concerns raised in recent enforcement actions included doctors issuing prescriptions without adequate evaluation and not conducting video consultations for first-time patients. Professional guidance also expects doctors to decide whether a case is appropriate for remote management or should be escalated to physical review.
For that reason, some patients may begin with teleconsultation but still be advised to attend a physical clinic visit. This is particularly relevant when there is diagnostic uncertainty, more complex medical history, red-flag symptoms, or a need for examination and baseline measurements. That is a clinical judgement issue, not just a logistics issue.
What may happen during the first consultation
A proper first consultation usually includes structured questioning rather than a brief request for medication. The doctor may ask about eating patterns, satiety, weight cycling, activity level, past attempts at diet or supervised programmes, sleep quality, alcohol intake, and personal goals. Those questions help identify whether the main issue is chronic obesity risk, uncontrolled diabetes, lifestyle barriers, medication-related weight gain, or another medical problem that needs different management. This is an inference from how Singapore obesity guidance frames assessment around health risk, comorbidities, behavioural factors, and realistic treatment goals.
The consultation is also where informed consent starts. That means the patient should understand what the medicine is for, how it is taken, what common side effects may happen, what symptoms require review, and why follow-up matters. Singapore professional guidance places patient welfare, competent care, and adequate standards of practice at the centre of prescribing decisions.
Why follow-up is part of the decision before prescribing
Receiving a prescription is usually not the end of the process. Doctors should also consider whether the patient can be monitored safely after initiation. HSA’s assessment of tirzepatide noted gastrointestinal adverse effects as the most common tolerability issues, and discontinuations due to adverse events did occur in studies, which supports the need for follow-up planning.
That follow-up may include review of symptoms, tolerability, changes in appetite, weight trend, hydration, bowel symptoms, and how the medicine fits with ongoing nutrition and lifestyle measures. The broader principle is that obesity and metabolic treatment are longitudinal forms of care, not one-off transactions. Singapore obesity guidance similarly describes weight treatment in terms of realistic goals, maintenance, and longer-term support.
How clinical evidence shapes the pre-prescription conversation
Clinical evidence is part of why doctors take this assessment seriously. In the SURMOUNT-1 trial, tirzepatide produced substantial and sustained weight reduction over 72 weeks in adults with obesity or overweight without diabetes, while HSA’s local benefit-risk review also observed that more tirzepatide-treated patients achieved at least 5% weight loss than placebo or comparator groups in the studies reviewed.
But trial results do not remove the need for screening. The same evidence base also highlights side effects, discontinuation risk, and the fact that outcomes are achieved under monitored clinical conditions. That is why the “before prescription” step is medically important: the doctor is deciding whether the patient is suitable for a supervised treatment pathway, not simply confirming demand for a drug.
What this means in Singapore clinics and telehealth settings
In Singapore, the practical pathway may differ from clinic to clinic, but the underlying requirement is the same: prescribing must follow proper medical assessment. Some services may begin with digital history-taking and teleconsultation, while others may require an in-person baseline review from the outset. Either way, the patient should expect more than a checkbox process.
This means a patient may be told that treatment is not appropriate, that further review is needed first, or that another approach should be prioritised. In a compliant care model, that is not a barrier to treatment; it is part of safe prescribing.
Takeaway
Before you receive a Mounjaro prescription in Singapore, the doctor should assess more than eligibility on paper. The pre-prescription stage usually involves reviewing weight-related risk, medical history, current medicines, treatment goals, side-effect considerations, and whether telehealth is suitable or an in-person review is needed. In Singapore’s regulatory and professional setting, this assessment is a core safety requirement, not an optional extra.
To understand how doctor assessment, treatment suitability, and telehealth prescribing fit into the wider Singapore care pathway for tirzepatide, you can refer to How Mounjaro Is Prescribed in Singapore: Clinics, Telehealth, and Medical Requirements.
FAQ
Can a teleconsultation be enough before Mounjaro is prescribed?
Sometimes, but not always. MOH has made clear that telemedicine must still involve proper clinical assessment, and recent enforcement actions highlighted concerns about first-time patients receiving prescriptions without adequate review. Some cases can be managed remotely, while others should be escalated to an in-person consultation.
Will every first consultation lead to a prescription?
No. A doctor may decide that tirzepatide is not appropriate, that more assessment is needed, or that another treatment strategy should be considered first. That reflects normal medical decision-making rather than denial of care.
Why do doctors ask about other health conditions before prescribing?
Because weight-related treatment is connected to wider metabolic risk. Conditions such as diabetes, hypertension, lipid disorders, and gastrointestinal history may change whether treatment is suitable and how it should be monitored.
Do BMI and waist measurements still matter if the discussion is about medication?
Yes. In Singapore, BMI and abdominal adiposity remain part of how doctors assess weight-related health risk, especially in Asian populations where lower BMI thresholds are used for public health action.
Why is follow-up discussed before treatment even starts?
Because safe prescribing includes planning for monitoring. Tirzepatide can cause gastrointestinal adverse effects and may require dose progression, counselling, and review of tolerability over time.